vorinostat has been researched along with Lymphopenia in 3 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Lymphopenia: Reduction in the number of lymphocytes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Only a minority of patients with high risk lymphoma will be cured with autologous transplant, so maintenance with vorinostat, an oral agent with activity in relapsed lymphoma, was studied starting day + 60 for 21 consecutive days followed by a week off for up to 11 cycles." | 9.20 | A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma. ( Andritsos, LA; Baiocchi, RA; Benson, DM; Bingman, A; Blum, K; Bowers, MA; Devine, SM; Earl, CT; Flynn, J; Geyer, S; Hade, EM; Hofmeister, CC; Humphries, K; Jaglowski, SM; Lozanski, G; Penza, S; Porcu, P; Vaughn, J; Williams, N, 2015) |
| "Only a minority of patients with high risk lymphoma will be cured with autologous transplant, so maintenance with vorinostat, an oral agent with activity in relapsed lymphoma, was studied starting day + 60 for 21 consecutive days followed by a week off for up to 11 cycles." | 5.20 | A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma. ( Andritsos, LA; Baiocchi, RA; Benson, DM; Bingman, A; Blum, K; Bowers, MA; Devine, SM; Earl, CT; Flynn, J; Geyer, S; Hade, EM; Hofmeister, CC; Humphries, K; Jaglowski, SM; Lozanski, G; Penza, S; Porcu, P; Vaughn, J; Williams, N, 2015) |
| "Oral vorinostat 200 mg was administered twice daily on days 1-14 along with 375 mg/m(2) of intravenous rituximab on day 1 of a 21-day cycle, continuing until disease progression or unacceptable toxicity." | 2.80 | A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma. ( Chen, R; Forman, SJ; Frankel, P; Htut, M; Kirschbaum, M; Mott, M; Nademanee, A; Nathwani, N; Popplewell, L; Rotter, A; Ruel, N; Siddiqi, T; Thomas, SH, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hofmeister, CC | 1 |
| Williams, N | 1 |
| Geyer, S | 1 |
| Hade, EM | 1 |
| Bowers, MA | 1 |
| Earl, CT | 1 |
| Vaughn, J | 1 |
| Bingman, A | 1 |
| Humphries, K | 1 |
| Lozanski, G | 1 |
| Baiocchi, RA | 1 |
| Jaglowski, SM | 1 |
| Blum, K | 1 |
| Porcu, P | 1 |
| Flynn, J | 1 |
| Penza, S | 1 |
| Benson, DM | 1 |
| Andritsos, LA | 1 |
| Devine, SM | 1 |
| Chen, R | 1 |
| Frankel, P | 1 |
| Popplewell, L | 1 |
| Siddiqi, T | 1 |
| Ruel, N | 1 |
| Rotter, A | 1 |
| Thomas, SH | 1 |
| Mott, M | 1 |
| Nathwani, N | 1 |
| Htut, M | 1 |
| Nademanee, A | 1 |
| Forman, SJ | 1 |
| Kirschbaum, M | 1 |
| Reilly, CM | 1 |
| Mishra, N | 1 |
| Miller, JM | 1 |
| Joshi, D | 1 |
| Ruiz, P | 1 |
| Richon, VM | 1 |
| Marks, PA | 1 |
| Gilkeson, GS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Histone Deacetylase (HDAC) Inhibition Using Vorinostat (SAHA) After Autologous Hematopoietic Stem Cell Transplantation for High Risk Lymphoma[NCT00561418] | Phase 1 | 23 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| A Phase II Study of Vorinostat (Suberoylanilide Hydroxamic Acid) Plus Rituximab in Indolent Non-Hodgkin's Lymphoma[NCT00720876] | Phase 2 | 30 participants (Actual) | Interventional | 2008-07-23 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Median follow up of living patients (NCT00561418)
Timeframe: Up to 5 years
| Intervention | months (Median) |
|---|---|
| Vorinostat (SAHA) | 23.2 |
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. (NCT00561418)
Timeframe: Up to 3 years
| Intervention | patients (Number) | |||
|---|---|---|---|---|
| Complete Response (CR) | Partial Response (PR) | Stable Disease(SD) | Not evaluable | |
| Vorinostat (SAHA) | 13 | 3 | 2 | 5 |
NCI CTCAE version 3.0 was used to assess Adverse Events (AE) Grade 1=Mild AE Grade 2=Moderate AE Grade 3=Severe AE Grade 4=Life-threatening or disabling AE (NCT00561418)
Timeframe: Up to 3 years
| Intervention | patients (Number) | ||||
|---|---|---|---|---|---|
| Fatigue (Grade 1, 2) | Lymphopenia (Grade 1-4) | Thrombocytopenia (Grade 1-3) | Leukopenia (Grade 1-3) | Anemia (Grade 1-3) | |
| Vorinostat (SAHA) | 12 | 11 | 11 | 10 | 10 |
Response was assessed according to the 2007 Cheson criteria using CT scans or PET: Complete Response (CR), Disappearance of all evidence of disease; Partial Response (PR), >=50% decrease in the Sum of the Product of Diameters (SPD) of up to 6 largest dominant masses and no increase in the size of other nodes; Overall Response (OR) = CR + PR. (NCT00720876)
Timeframe: After every 3 cycles, up to 1 year after the start of treatment
| Intervention | percentage of participants (Number) |
|---|---|
| Vorinostat and Rituximab | 46 |
ProgressionRelapse is defined using the 2007 Cheson criteria, as appearance of any new lesion more than 1.5 cm in any axis during or at the end of therapy; or at least a 50% increase for nadir in the SPD of any previously involved nodes; or at least a 50% increase in the longest diameter of any singe previously identified node more than 1 cm in its short axis. Estimated using the product-limit method of Kaplan and Meier. (NCT00720876)
Timeframe: Until disease progress
elapse, up to 1 year after the start of treatment
| Intervention | Months (Median) |
|---|---|
| Vorinostat and Rituximab | 29.2 |
Grade 3 & 4 toxicities at least possible related to study drugs during any cycle of treatment. Toxicity graded according to Common Terminology Criteria for Adverse Events version 3.0. (NCT00720876)
Timeframe: 3 weeks after the stop of treatment
| Intervention | Participants (Count of Participants) | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neutrophil count decreased | Platelet count decreased | Hemoglobin decreased | Lymphocyte count decreased | Hypotension | Chills | Fatigue | Dehydration | Diarrhea | Kidney infection | Pneumonia | Sepsis | Urinary tract infection | Localized edema | Alanine aminotransferase increased | Aspartate aminotransferase increased | Blood glucose increased | Serum phosphate decreased | Serum potassium decreased | Muscle weakness | Syncope | Hypoxia | Pneumonitis | Thrombosis | Vascular access complication | |
| Vorinostat and Rituximab | 3 | 5 | 1 | 7 | 2 | 1 | 9 | 3 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 3 | 3 | 2 | 1 | 1 | 1 | 1 | 4 | 1 |
2 trials available for vorinostat and Lymphopenia
| Article | Year |
|---|---|
A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma.
Topics: Administration, Oral; Adult; Aged; Child; Combined Modality Therapy; Diarrhea; Disease-Free Survival | 2015 |
A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antine | 2015 |
1 other study available for vorinostat and Lymphopenia
| Article | Year |
|---|---|
Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid.
Topics: Adjuvants, Immunologic; Animals; Anti-Inflammatory Agents, Non-Steroidal; Autoantibodies; CD3 Comple | 2004 |